Clinical Study of Multimodal Ablation Remodeling Immunosensitized PD-1 in the Treatment of Pancreatic Cancer With Liver Metastasis

Launched by SHANGHAI GENERAL HOSPITAL, SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE · Mar 6, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment approach for patients with pancreatic cancer that has spread to the liver. The treatment combines several methods: a special technique called multimodal ablation to target the tumors, along with immunotherapy and chemotherapy to help the body fight the cancer more effectively. The goal is to see if this combination can improve outcomes for patients with this challenging condition.

To be eligible for the trial, participants need to be between 18 and 70 years old and must have been newly diagnosed with pancreatic cancer that has spread to the liver, with no other organ involvement. The trial is looking for patients who have a limited number of small tumors in the liver. Those with severe liver issues or other serious health problems may not be able to participate. If you join the trial, you will receive the new treatment while being closely monitored by healthcare professionals. This study is currently recruiting participants, so if you or a loved one fits the criteria, it could be an opportunity to access innovative care.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. age 18-70 years old, gender is not limited;
• • 2. Newly diagnosed pancreatic cancer with liver metastasis confirmed by pathology or consistent with clinical diagnosis, and no metastases to organs other than the liver;
• • 3. Imaging evaluable tumors with safe access to puncture;
• • 4. The number of half liver tumors ≤3 and the size of each tumor ≤3 cm;
• • 5. ECOG PS score ≤2 points, expected survival \> 3 months.
• Exclusion Criteria:
• • 1. Liver function Child-Pugh grade C, severe jaundice, especially obstructive jaundice;
• • 2. The liver is significantly atrophy, the tumor is too large, and the ablation range needs to reach one-third of the liver volume;
• • 3. Expected survival \< 3 months;
• • 4. serious heart, lung, liver and kidney dysfunction and coagulation dysfunction;
• • 5. Uncontrolled co-morbidities, including poorly controlled hypertension or diabetes, persistent active infections, or mental illness or social conditions that may affect participants' compliance with the study;
• • 6. refractory ascites, pleural fluid or bad fluid;
• • 7. Pregnancy or breastfeeding;
• • 8. The researcher considers that there are any other factors that are not suitable for inclusion or affect the participant's participation in the study.